Drug details
Amjevita (adalimumab-atto)
type of DMARDs, TNF Inhibitors, Monoclonal Antibodies, Antipsoriatics, Systemic, Inflammatory Bowel Disease Agents
Amjevita (adalimumab-atto) injection is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).
The drug is often used to treat Ankylosing spondylitis , Arthritis , Psoriatic arthritis , Ulcerative colitis .
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- loss of appetite,
- dark urine,
- vomiting,
- fever,
- swollen glands,
- night sweats,
- general feeling of illness,
- joint and muscle pain,
- skin rash,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- pain in your upper stomach that may spread to your shoulder,
- feeling full after eating only a small amount,
- weight loss,
- new or worsening psoriasis (raised, silvery flaking of the skin),
- sore or bump on your skin that does not heal,
- body aches,
- tiredness,
- stomach pain,
- clay-colored stools,
- yellowing of the skin or eyes (jaundice),
- joint pain or swelling,
- chest pain,
- patchy skin color that worsens in sunlight,
- numbness,
- tingling,
- dizziness,
- vision problems,
- weakness in your arms or legs, and
- fever with ongoing cough
- right-sided upper stomach pain,
The following drugs are related to Amjevita, either as a replacement or used together:
- Orencia (abatacept)
- Humira (adalimumab injection solution for subcutaneous administration)
- Kineret (anakinra)
- Arava (leflunomide)
- Ridaura (auranofin)
- Cimzia (certolizumab pegol injection)
- Enbrel (etanercept)
- Myochrysine (gold sodium thiomalate)
- Inflectra (infliximab-dyyb intravenous injection)
- Remicade (infliximab)
- Kimyrsa (oritavancin for injeciton)
- Rituxan (rituximab)